Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is
significantly worse than that of aggressive B cell lymphomas. The prospects of elderly
patients are especially poor, with an estimated disease free survival of only 25% after three
years. Previous phase II trials have demonstrated a significant activity of the monoclonal
anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators
thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense
CHOP-14 in patients with previously untreated peripheral T cell lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
University of Göttingen
Collaborators:
German High-Grade Non-Hodgkin's Lymphoma Study Group Nordic Lymphoma Group